{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T17:01:27Z","timestamp":1756573287517},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40266-018-0610-y","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T20:14:30Z","timestamp":1542053670000},"page":"1089-1098","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dabigatran Versus Rivaroxaban for Secondary Stroke Prevention in Patients with Atrial Fibrillation Rehabilitated in Skilled Nursing Facilities"],"prefix":"10.1007","volume":"35","author":[{"given":"Matthew","family":"Alcusky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L.","family":"Hume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Tjia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate L.","family":"Lapane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"key":"610_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.mayocp.2014.07.010","volume":"89","author":"WA Rocca","year":"2014","unstructured":"Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, et al. The prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and ethnicity. Mayo Clin Proc. 2014;89:1336\u201349.","journal-title":"Mayo Clin Proc"},{"key":"610_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/gerona\/glv013","volume":"70","author":"CJ Charlesworth","year":"2015","unstructured":"Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988\u20132010. J Gerontol Ser A Biol Sci Med Sci. 2015;70:989\u201395.","journal-title":"J Gerontol Ser A Biol Sci Med Sci"},{"key":"610_CR3","doi-asserted-by":"publisher","first-page":"108785","DOI":"10.4061\/2011\/108785","volume":"2011","author":"T Russo","year":"2011","unstructured":"Russo T, Felzani G, Marini C. Stroke in the very old: a systematic review of studies on incidence, outcome, and resource use. J Aging Res. 2011;2011:108785.","journal-title":"J Aging Res."},{"key":"610_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/MLR.0b013e3181e359df","volume":"48","author":"MB Buntin","year":"2010","unstructured":"Buntin MB, Colla CH, Deb P, Sood N, Escarce JJ. Medicare spending and outcomes after postacute care for stroke and hip fracture. Med Care. 2010;48:776\u201384.","journal-title":"Med Care"},{"key":"610_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/CIRCOUTCOMES.114.000907","volume":"8","author":"PA Patel","year":"2015","unstructured":"Patel PA, Zhao X, Fonarow GC, Lytle BL, Smith EE, Xian Y, et al. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ Cardiovasc Qual Outcomes. 2015;8:383\u201392.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"610_CR6","doi-asserted-by":"publisher","first-page":"e77694","DOI":"10.1371\/journal.pone.0077694","volume":"8","author":"P Sardar","year":"2013","unstructured":"Sardar P, Chatterjee S, Wu WC, Lichstein E, Ghosh J, Aikat S, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One. 2013;8:e77694.","journal-title":"PLoS One"},{"key":"610_CR7","doi-asserted-by":"publisher","first-page":"e7097","DOI":"10.1136\/bmj.e7097","volume":"345","author":"LH Rasmussen","year":"2012","unstructured":"Rasmussen LH, Larsen TB, Graungaard T, Skjoth F, Lip GYH. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097.","journal-title":"BMJ"},{"key":"610_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40256-016-0189-9","volume":"17","author":"I Hernandez","year":"2017","unstructured":"Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the us medicare part D data. Am J Cardiovasc Drugs. 2017;17:37\u201347.","journal-title":"Am J Cardiovasc Drugs."},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","volume":"176","author":"DJ Graham","year":"2016","unstructured":"Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, Southworth MR. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662\u201371.","journal-title":"JAMA Intern Med."},{"issue":"2","key":"610_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.09.007","volume":"27","author":"Y Kanai","year":"2018","unstructured":"Kanai Y, Oguro H, Tahara N, Matsuda H, Takayoshi H, Mitaki S, et al. Analysis of recurrent stroke volume and prognosis between warfarin and four non-vitamin k antagonist oral anticoagulants\u2019 administration for secondary prevention of stroke. J Stroke Cerebrovasc Dis. 2018;27(2):338\u201345.","journal-title":"J Stroke Cerebrovasc Dis."},{"issue":"5","key":"610_CR11","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.11.032","volume":"27","author":"T Nakase","year":"2018","unstructured":"Nakase T, Moroi J, Ishikawa T. Outcome of secondary stroke prevention in patients taking non-vitamin K antagonist oral anticoagulants. J Stroke Cerebrovasc Dis. 2018;27(5):1174\u20137.","journal-title":"J Stroke Cerebrovasc Dis."},{"issue":"7","key":"610_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jamda.2012.06.002","volume":"13","author":"D Saliba","year":"2012","unstructured":"Saliba D, Buchanan J. Making the investment count: revision of the minimum data set for nursing homes, MDS 3.0. J Am Med Dir Assoc. 2012;13(7):602\u201310.","journal-title":"J Am Med Dir Assoc."},{"issue":"4","key":"610_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221\u20138.","journal-title":"Curr Epidemiol Rep."},{"key":"610_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCOUTCOMES.113.000743","volume":"7","author":"H Kumamaru","year":"2014","unstructured":"Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, et al. Validity of claims-based stroke algorithms in contemporary medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7:611\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"610_CR15","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","volume":"68","author":"BA Steinberg","year":"2016","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, ORBIT-AF Investigators and Patients, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68:2597\u2013604.","journal-title":"J Am Coll Cardiol"},{"key":"610_CR16","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69:2779\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"610_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, RE-LY Steering Committee and Investigators, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med."},{"key":"610_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","volume":"20","author":"A Cunningham","year":"2011","unstructured":"Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"610_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.thromres.2010.03.009","volume":"126","author":"RH White","year":"2010","unstructured":"White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res. 2010;126(1):61\u20137.","journal-title":"Thromb Res"},{"key":"610_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","volume":"148","author":"Y Kiyota","year":"2004","unstructured":"Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99\u2013104.","journal-title":"Am Heart J"},{"key":"610_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"610_CR22","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes results from the national registry of atrial fibrillation. JAMA. 2001;285:2864\u201370.","journal-title":"JAMA"},{"key":"610_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2005.04.029","volume":"46","author":"WC Winkelmayer","year":"2005","unstructured":"Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from medicare claims data: a validation study. Am J Kidney Dis. 2005;46:225\u201332.","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"610_CR24","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MLR.0000000000000334","volume":"55","author":"KS Thomas","year":"2017","unstructured":"Thomas KS, Dosa D, Wysocki A, Mor V. The Minimum Data Set 3.0 Cognitive Function Scale. Med Care. 2017;55(9):e68\u201372.","journal-title":"Med Care."},{"key":"610_CR25","unstructured":"Centers for Medicare and Medicaid Services. MDS 3.0 RAI Manual. \n                    https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/NursingHomeQualityInits\/MDS30RAIManual.html\n                    \n                  . Published October 1, 2016. Accessed 1 Sept 2017."},{"key":"610_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0895-4356(89)90065-6","volume":"42","author":"S Shah","year":"1989","unstructured":"Shah S, Vanclay F, Cooper B, Duckworth D, Dombovy M. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42:703\u20139.","journal-title":"J Clin Epidemiol"},{"key":"610_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1160\/TH16-10-0757","volume":"117","author":"V Raparelli","year":"2017","unstructured":"Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2017;117:209\u201318.","journal-title":"Thromb Haemost"},{"key":"610_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ahj.2017.03.024","volume":"189","author":"BA Steinberg","year":"2017","unstructured":"Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017;189:40\u20137.","journal-title":"Am Heart J"},{"key":"610_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/CIRCOUTCOMES.109.850883","volume":"4","author":"JH Lichtman","year":"2011","unstructured":"Lichtman JH, Naert L, Allen NB, Watanabe E, Jones SB, Barry LC, et al. Use of antithrombotic medications among elderly ischemic stroke patients. Circ Cardiovasc Qual Outcomes. 2011;4:30\u20138.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"25\u201336","key":"610_CR30","first-page":"e2","volume":"10","author":"PK Ghaswalla","year":"2012","unstructured":"Ghaswalla PK, Harpe SE, Slattum PW. Warfarin use in nursing home residents: results from the 2004 national nursing home survey. Am J Geriatr Pharmacother. 2012;10(25\u201336):e2.","journal-title":"Am J Geriatr Pharmacother."},{"key":"610_CR31","doi-asserted-by":"publisher","first-page":"e1S","DOI":"10.1378\/chest.11-2290","volume":"141","author":"S MacLean","year":"2012","unstructured":"MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, et al. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e1S\u201323S.","journal-title":"Chest"},{"key":"610_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"610_CR33","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1161\/STROKEAHA.117.017474","volume":"48","author":"CI Coleman","year":"2017","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48:2142\u20139.","journal-title":"Stroke"},{"issue":"356","key":"610_CR34","doi-asserted-by":"publisher","first-page":"j510","DOI":"10.1136\/bmj.j510","volume":"10","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skj\u00f8th F, S\u00f8gaard M, Kj\u00e6ldgaard JN, Lip GY, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;10(356):j510.","journal-title":"BMJ"},{"key":"610_CR35","unstructured":"Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2012. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022512s000lbl.pdf\n                    \n                  . Accessed 25 June 2017."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0610-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T19:32:44Z","timestamp":1573587164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0610-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"13 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Massachusetts Medical School Institutional Review Board approved this study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of research formal consent is not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"At the time the study was conducted, Dr Alcusky was funded by the National Center for Advancing Translational Sciences (TL1TR001454). Dr McManus was funded by the National Heart, Lung, and Blood Institute (RO1HL126911, RO1HL135219, RO1HL136660, R15HL121761). Partial support for Dr Goldberg was provided by the National Heart, Lung, and Blood Institute (1R01HL126911-01A1, 5R01HL125089-02, 5R01HL115295-05).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Tjia is a consultant for CVS Health. Dr. Alcusky, Dr. Goldberg, Dr. Fisher, Dr. Lapane, and Dr. Hume have no interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}